When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

On October 23, according to Caixin, starting from the end of the second quarter, the wave of vitamin price increases successfully drove a substantial increase in manufacturers' Q3 profits. Following Zhejiang Garden Biopharmaceutical's positive Q3 performance, the leading vitamin producer, Zhejiang NHU (002001.SZ), also achieved a record high profit for a single quarter in Q3.

Tonight, Zhejiang NHU announced its third-quarter report, in the reporting period, the company achieved revenue of 15.782 billion yuan, a year-on-year increase of 43.31%; net profit attributable to shareholders was 3.99 billion yuan, a year-on-year increase of 89.87%. Looking at the quarterly performance, the company achieved a net profit attributable to shareholders of 1.785 billion yuan in the third quarter, a nearly 190% year-on-year increase, setting a new record for single-quarter profit for the company.

Prior to Zhejiang NHU, Zhejiang Garden Biopharmaceutical also disclosed its third-quarter report, showing a significant increase in profits in Q3 this year, with a single-quarter net profit attributable to shareholders of nearly 0.1 billion yuan, a year-on-year increase of over 213%. Thanks to the strong performance in Q3, the company achieved revenue of 0.938 billion yuan in the first three quarters of this year, a year-on-year increase of 4.43%; net profit attributable to shareholders was 0.241 billion yuan, a year-on-year increase of 62.13%.

It is reported that the outstanding performance of vitamin manufacturers is mainly attributed to the gross profit increase brought about by product price hikes. Market data shows that in the first half of this year, the overall performance of the vitamin market was relatively weak. Towards the end of the second quarter, Zhejiang Garden Biopharmaceutical's core product, vitamin D3, was the first to raise prices. Subsequently, stimulated by the accident at the German BASF factory, the price hike effect spread to various types such as Vitamin A and Vitamin B, initiating a boom cycle for the entire industry.

Caixin reporters learned from Shanghai Ganglian E-Commerce Holdings that the current round of vitamin price increases peaked in August and September this year. Apart from the relatively firm price of vitamin D3, prices of most varieties are gradually declining, but still significantly higher than the lows of the first half of the year, remaining at relatively high levels.

Currently, the overall trading atmosphere in the vitamin market is not optimistic, with most varieties entering a consolidation phase. Coupled with the limited amount of market goods flowing to end consumers, there is not much room for substantial price increases. However, there has been an increase in inquiries for Vitamin A and Vitamin E, strengthening the market's expectations for a price increase in the second half of the year for Vitamin E.

Against this background, the price increase bonus is expected to continue into Q4, but related manufacturers may face some pressure in maintaining high profit growth in Q4. Previously, the management of Zhejiang Garden Biopharmaceutical also stated publicly that this round of price hikes will have a positive impact on the company's operational performance in the second half of the year.